ArticleACS nano2025
Artificial Intelligence-Guided Cancer Engineering for Tumor Normalization Executed by Tumor Lysosomal-Triggered Supramolecular Chiral Peptide.
Article in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Leveraging the crosstalk between cGAS-STING and pyroptosis by nanomedicine to enhance antitumor immunity.Journal of nanobiotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer engineering for tumor normalization offers a promising therapeutic strategy to reverse malignant cells and their supportive tumor microenvironment into a more benign state. Herein, an artificial intelligence (AI) approach was developed using mRNA data from patients with lung adenocarcinoma to facilitate the identification of aberrant signaling pathways, specifically focusing on PD-L1, Wnt, and macropinocytosis. Targeting these characteristics, we have developed a supramolecular construct called cancer corrector (CCtor) with the aim of harnessing the enhanced macropinocytosis observed in cancer cells. Undergoing cleavage and subsequent drug release triggered by the lysosomal protease in cancer cells, CCtor rectifies the aberrant hyperactivity of both Wnt and PD-L1 signaling pathways. This dual-action therapeutic strategy not only restores normalcy to cancer cells but also exerts an exceptionally robust therapeutic effect. This work exemplifies a future direction for cancer therapies by combining AI with molecular engineering to significantly improve patient outcomes through tumor behavior normalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.